Esperion Therapeutics, Inc.
ESPR
$2.18
-$0.01-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.58% | -52.81% | 114.30% | 52.00% | 186.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.58% | -52.81% | 114.30% | 52.00% | 186.33% |
| Cost of Revenue | 32.18% | 87.81% | 25.40% | -2.05% | -6.28% |
| Gross Profit | -0.34% | -81.71% | 963.65% | 319.64% | 1,609.00% |
| SG&A Expenses | -10.58% | 2.40% | -18.71% | 20.26% | 30.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.66% | 33.03% | -1.45% | 10.01% | 13.38% |
| Operating Income | 175.11% | -130.57% | 89.57% | 41.79% | 106.96% |
| Income Before Tax | 79.45% | -166.30% | 62.16% | 28.43% | -24.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 79.45% | -166.30% | 62.16% | 28.43% | -24.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.45% | -166.30% | 62.16% | 28.43% | -24.01% |
| EBIT | 175.11% | -130.57% | 89.57% | 41.79% | 106.96% |
| EBITDA | 175.62% | -130.52% | 89.63% | 41.83% | 106.98% |
| EPS Basic | 80.37% | -157.23% | 78.26% | 58.91% | 28.24% |
| Normalized Basic EPS | -39.93% | -157.21% | 79.96% | 58.92% | 89.90% |
| EPS Diluted | 80.37% | -162.56% | 78.26% | 58.91% | 28.24% |
| Normalized Diluted EPS | -39.93% | -164.10% | 79.96% | 58.92% | 89.90% |
| Average Basic Shares Outstanding | 4.64% | 15.87% | 73.99% | 74.25% | 72.82% |
| Average Diluted Shares Outstanding | 4.64% | 3.42% | 73.99% | 74.25% | 72.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |